News | February 21, 2022
SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
The companies plan to use the proceeds to retire debt and expand operations
The companies plan to use the proceeds to retire debt and expand operations
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Evonik invests in start-up to improve patient recovery after open-chest surgery
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Subscribe To Our Newsletter & Stay Updated
